Latest filing published 28 Mar 2013 for PROGENICS PHARMACEUTICALS INC, €2,065.
Insider track record
No signal scores available.
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Mark Robert Baker: trading record in brief
This profile gathers the share dealings of Mark Robert Baker in Progenics Pharmaceuticals Inc. Over a trading history stretching from 3 January 2006 to 27 March 2013, the count stands at 110 filings.
Both buying and selling appear: 57 purchases worth €214k, against 3 sales worth €22k. On balance, insiders were net buyers of €192k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 26 share grants and 24 option exercises. 2013 to date brings 8 purchases and no sales.
Half of the purchases are above €787 and half below.
The newest entry dates from 28 March 2013: an open-market purchase of €2,065, in Progenics Pharmaceuticals Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Mark Robert Baker
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 500 shares@ US$5.31Common StockSEC:0001447348-13-000010:0Canonical exit: 25 Jun 2013 (T+90)
- 50 shares@ US$5.34Common StockSEC:0001447348-13-000010:1Canonical exit: 25 Jun 2013 (T+90)
- 100 shares@ US$5.36Common StockSEC:0001447348-13-000010:2Canonical exit: 25 Jun 2013 (T+90)
- 500 shares@ US$2.71Common StockSEC:0001447348-13-000004:0Canonical exit: 28 May 2013 (T+90)
- 535 shares@ US$2.72Common StockSEC:0001447348-13-000004:1Canonical exit: 28 May 2013 (T+90)
- 227 shares@ US$2.75Common StockSEC:0001447348-13-000004:2Canonical exit: 28 May 2013 (T+90)
- 900 shares@ US$2.82Common StockSEC:0001447348-13-000002:0Canonical exit: 22 Apr 2013 (T+90)
- 315 shares@ US$2.83Common StockSEC:0001447348-13-000002:1Canonical exit: 22 Apr 2013 (T+90)
- 1,142 shares@ US$3.01Common StockSEC:0001447348-12-000049:0Canonical exit: 26 Mar 2013 (T+90)
- 300 shares@ US$2.12Common StockSEC:0001447348-12-000047:0Canonical exit: 26 Feb 2013 (T+90)
- 100 shares@ US$2.12Common StockSEC:0001447348-12-000047:1Canonical exit: 26 Feb 2013 (T+90)
- 100 shares@ US$2.13Common StockSEC:0001447348-12-000047:2Canonical exit: 26 Feb 2013 (T+90)
- 1,000 shares@ US$2.13Common StockSEC:0001447348-12-000047:4Canonical exit: 26 Feb 2013 (T+90)
- 7 shares@ US$2.14Common StockSEC:0001447348-12-000047:5Canonical exit: 26 Feb 2013 (T+90)
- 11,800 shares@ US$1.96Common StockSEC:0001441844-12-000004:0Canonical exit: 17 Feb 2013 (T+90)
- 49,793 shares@ US$1.82Common StockSEC:0001441844-12-000003:0Canonical exit: 14 Feb 2013 (T+90)
- 48,833 shares@ US$1.69Common StockSEC:0001441844-12-000002:0Canonical exit: 13 Feb 2013 (T+90)
- 1,162 shares@ US$2.96Common StockSEC:0001447348-12-000045:0Canonical exit: 22 Jan 2013 (T+90)
- 1,036 shares@ US$3.32Common StockSEC:0001447348-12-000043:0Canonical exit: 25 Dec 2012 (T+90)
- 815 shares@ US$4.23Common StockSEC:0001447348-12-000042:0Canonical exit: 20 Nov 2012 (T+90)
- 346 shares@ US$10.04Common StockSEC:0001447348-12-000041:0Canonical exit: 23 Oct 2012 (T+90)
- 75 shares@ US$9.21Common StockSEC:0001447348-12-000039:0Canonical exit: 25 Sept 2012 (T+90)
- 21 shares@ US$9.27Common StockSEC:0001447348-12-000039:1Canonical exit: 25 Sept 2012 (T+90)
- 179 shares@ US$9.29Common StockSEC:0001447348-12-000039:2Canonical exit: 25 Sept 2012 (T+90)
- 100 shares@ US$9.29Common StockSEC:0001447348-12-000039:3Canonical exit: 25 Sept 2012 (T+90)
25 of 109 declarations
